デュテプラーゼ

デュテプラーゼ 化学特性,用途語,生産方法

• 効能

  血栓溶解薬, 組織プラスミノーゲン活性化薬 (t-PA)

• 説明

  Duteplase, a nearly pure double-chain recombinant tissue-type plasminogen activator (rt-PA), was introduced in Japan for the treatment of acute myocardial infarction. Similar to other thrombolytic agents, duteplase acts by converting the proenzyme plasminogen to the active enzyme plasmin, resulting in fibrinolysis and varying degrees of depletion of circulating fibrinogen, factor V and factor VIII. In patients with acute myocardial infarction, treatment with duteplase induced patency rate of infarct-related artery at 90 minutes by up to 69%. Compared with alteplase, a single-chain rt-PA, duteplase has similar activity but a slower clearance rate and thus lower doses of duteplase have a similar therapeutic effect to alteplase.

• Originator

  SumItomo (Japan)

• brand name

  Solclot

デュテプラーゼ 生産企業

Global(4)Suppliers

120608-46-0, デュテプラーゼ キーワード